<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="412">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 16, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347382</url>
  </required_header>
  <id_info>
    <org_study_id>1.6/M.Edu/141/2020</org_study_id>
    <nct_id>NCT04347382</nct_id>
  </id_info>
  <brief_title>Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT</brief_title>
  <acronym>WUHAN Trail</acronym>
  <official_title>With Uncontroversial Honey And Nigella Sativa (WUHAN) Treatment for Noval Coronavirus Infection; Randomized, Controlled, Double Blind, Investigator Initiated Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheikh Zayed Federal Postgraduate Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Hospital Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheikh Zayed Federal Postgraduate Medical Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Nigella Sativa/ Black Cummins (2gm seed powder in a capsule
      orally) and 30ml of honey stirred in 250ml of distilled water 12 hourly till patient becomes
      asymptomatic or a maximum of 14 days with standard hospital care vs standard hospital care
      alone with placebo capsule and 250ml water, in clearing the COVID-19 nucleic acid from throat
      and nasal swab, lowering disease detrimental effects on HRCT chest/X-ray and severity of
      symptoms along with duration of hospital stay till day 14th day of follow up and 30 days
      mortality (primary outcomes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cohort, adaptive, randomized, double armed group, controlled, Investigator Initiated
      interventional study is designed to demonstrate the superiority of a combination of black
      cumin with honey over standard care in SARS-Cov-2 (COVID-19) infected patients who consent to
      randomization following a new diagnosis in Pakistan with an SSC-2 score of &gt; 5 with positive
      RT-PCR of COVID-19. Investigators will follow up with participants every 4th day to access
      clinically the severity of symptoms along with RT-PCR and HRCT chest or X-ray to access the
      disease progression.Those positive on 8th day will be followed up further for monitoring of
      primary end points. Findings of this trial are expected to help establishing a new remedy for
      the treatment of this pandemic giving mortality benefit along with earlier decrease in viral
      load and lesser complications rate caused by SARS-Cov-2 virus
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days required to get a positive COVID-19 PCR to negative</measure>
    <time_frame>upto max 14 days</time_frame>
    <description>RT-PCR will be done on admission day (0 day) and then after every 4th day for 14 days or till the symptoms resolved and RT-PCR gets negative. RT-PCR will only be shown as positive or negative (as per limitation of Pakistan).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRCT/ X-ray findings of disease prgression</measure>
    <time_frame>upto max 14 days</time_frame>
    <description>HRCT will be conducted at admission day (0-day) and a total of maximum four CT-scan will be conducted after every 4th day. The minimum and score at which we label covid-19 positive will be 5 and 25 respectively using internationally standard nomenclature as described by Fleischner Society glossary and peer-reviewed literature on viral pneumonia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of symptoms progression</measure>
    <time_frame>upto max 14 days</time_frame>
    <description>Clinically disease progression will be evaluated depending upon the severity of symptoms being classified as mild, moderate and severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Hospital Saty</measure>
    <time_frame>upto max 14 day</time_frame>
    <description>Duration of hospital stay would be categorized as the number of days the patient stayed in the ward during treatment. The date of admission and date of discharge would give us total duration of stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30 days mortality rate in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation at room air</measure>
    <time_frame>upto max of 14 days</time_frame>
    <description>every 4th day oxygen saturation at room air will be checked to evaluate the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral myocarditis</measure>
    <time_frame>upto max 14 days</time_frame>
    <description>Involvement of cardiac complications will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute respiratory Distress Syndrome</measure>
    <time_frame>upto max 14 days</time_frame>
    <description>Lethal complication like ARDS will be assessed to evalute disease severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Nigella Sativa &amp; Honey Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Nigella Sativa seed Powder (2gm twice daily in capsule upto a max of 14 days) Drug: Natural Honey (30ml orally twice a day upto a max of 14 days)
along with standard medical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard supportive medical care given in Corona center of Mayo Hospital, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Honey</intervention_name>
    <description>30ml Natural Honey orally BD</description>
    <arm_group_label>Nigella Sativa &amp; Honey Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella Sativa / Black Cumin</intervention_name>
    <description>Capsule 2gm seed powder orally BD</description>
    <arm_group_label>Nigella Sativa &amp; Honey Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Empty capsule with 250ml of distilled water</description>
    <arm_group_label>Standard Medical Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result with SSC-2 score &gt;
             5 Patients admitted in Corona center of Mayo Hospital

        Exclusion Criteria:

          -  Participants not giving consent. Pregnant and lactating females. History of allergy to
             any drug being administered in this study Severely terminally ill patients Patients on
             Nil Per Oral
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoaib Ashraf, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University, Boston, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Ashraf, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Of Veterinary &amp; Animal Sciences, Lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sohaib Ashraf, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Post-Graduate Medical Institute, Lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Ahmad Imran, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaikh Zayed Hospital, Lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayesha Hamayun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaikh Khalifa Bin Zayed Al-Nahyan Medical &amp; Dental College, Lahore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohaib Ashraf, MBBS</last_name>
    <phone>+923334474523</phone>
    <email>sohaib-ashraf@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Ahmad Imran, MBBS</last_name>
    <phone>+923338110708</phone>
    <email>ahmad.ammy93@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Hospital, Kingedward Medical University</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohaib Ashraf, MBBS</last_name>
      <phone>+923334474523</phone>
      <email>sohaib-ashraf@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmad Imran, MBBS</last_name>
      <phone>+923338110708</phone>
      <email>ahmad.ammy93@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sohaib Ashraf, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad Imran, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayesha Hamayun, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Ulasli M, Gurses SA, Bayraktar R, Yumrutas O, Oztuzcu S, Igci M, Igci YZ, Cakmak EA, Arslan A. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep. 2014 Mar;41(3):1703-11. doi: 10.1007/s11033-014-3019-7. Epub 2014 Jan 12.</citation>
    <PMID>24413991</PMID>
  </reference>
  <reference>
    <citation>Oyero OG, Toyama M, Mitsuhiro N, Onifade AA, Hidaka A, Okamoto M, Baba M. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A NIGELLA SATIVA SEED FORMULATION. Afr J Tradit Complement Altern Med. 2016 Sep 29;13(6):144-148. doi: 10.21010/ajtcam.v13i6.20. eCollection 2016.</citation>
    <PMID>28480371</PMID>
  </reference>
  <reference>
    <citation>Khan SU, Anjum SI, Rahman K, Ansari MJ, Khan WU, Kamal S, Khattak B, Muhammad A, Khan HU. Honey: Single food stuff comprises many drugs. Saudi J Biol Sci. 2018 Feb;25(2):320-325. doi: 10.1016/j.sjbs.2017.08.004. Epub 2017 Aug 16. Review.</citation>
    <PMID>29472785</PMID>
  </reference>
  <reference>
    <citation>Forouzanfar F, Bazzaz BS, Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci. 2014 Dec;17(12):929-38. Review.</citation>
    <PMID>25859296</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheikh Zayed Federal Postgraduate Medical Institute</investigator_affiliation>
    <investigator_full_name>Sohaib Ashraf</investigator_full_name>
    <investigator_title>Post-Graduate Resident Cardiology</investigator_title>
  </responsible_party>
  <keyword>SARS-Cov-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Honey</keyword>
  <keyword>Nigella Sativa</keyword>
  <keyword>Black Cumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

